Crossmark

The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases

Published Online: 2019-12-11

Published Print: 2020-03

Authors

Kitadai, Rui

Okuma, Yusuke https://orcid.org/0000-0001-5743-0149
Hakozaki, Taiki

Hosomi, Yukio
License Information

Text and Data Mining valid from 2019-12-11

Version of Record valid from 2019-12-11
More Information

Article History

Received: 9 October 2019

Accepted: 2 December 2019

First Online: 11 December 2019

Compliance with ethical standards

:

: YO has received honoraria from AstraZeneca Japan, Boehringer-Ingelheim Japan, Chugai Pharmaceutical Co. Ltd., Eli Lily Co. Ltd., MSD K. K., and Ono Pharmaceutical Co. The other authors have no conflicts of interest to disclose.

: This study protocol was approved by the Ethics Committee of the Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital (#2272) and was conducted in accordance with the tenets of the Declaration of Helsinki.

: Instead of obtaining informed consent from each patient, participants or their next of kin were given the opportunity to opt-out.

Document is current